Applied Therapeutics Stock (NASDAQ: APLT)

Applied Therapeutics

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

APLT

IIPR

MESO

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Biotech

Health Care

Legal

General

Adrian Alexandru files a securities lawsuit against Applied Therapeutics, alleging the company misled investors about clinical trials for govorestat.

Penny Stock Applied Therapeutics&#39; FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Top 10 Shows On Netflix India This Week

Price Target

AFRM

DELL

FLYW

NFLX

TMUS

Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics Inc

Press Releases

APLT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - APLT

Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky

APLT FRAUD ALERT: A Class Action has been Filed against Applied Therapeutics for Securities Fraud – Contact BFA Law by Today's Deadline (NASDAQ:APLT)

DEADLINE ALERT for APLT and KSPI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Applied Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT

Management

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission

Earnings

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results

NET Power Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 17, 2025 Deadline to file Lead Plaintiff Motion

KSPI

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Biomea Fusion

Cabaletta Bio

Citius Oncology

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

IGM Biosciences

Immix Biopharma

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MAIA Biotechnology

Metagenomi

Pyxis Oncology

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

Vor Biopharma

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Exicure

RBC Capital

Citigroup

Baird

Leerink Partners

Comments

Applied Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell